Immuron reveals anti-COVID potential, raises $28 million
Hot on the heels of reporting anti-Covid-19 action by one of the drugs it is developing, biotechnology company Immuron has raised $28 million (US$20 million) from institutional investors.
https://www.aumanufacturing.com.au/immuron-reveals-anti-covid-potential-raises-28-million
Filter by Year:
- Immuron partnering with Walter Reid Army Institute of Research to test Travelan against Shigella, ETEC, Vibrio cholerae and Campylobacter jejuni isolates (2020, WRAIR's Investigator's Dispatch)
- Immuron (ASX:IMC) enters research agreement with Monash University
- Walter Reid Army Institute of Research 2019 Year in Review
- Immuron reveals anti-COVID potential, raises $28 million
- Diarrhea: A major health issue for Americans travelling abroad
- Could Immuron’s (ASX:IMC) traveller’s diarrhoea treatment be used to fight COVID-19?
This category is empty! Please try another category or use our search function to find what you are looking for. If you require further assistance please contact us.
